Senores Pharmaceuticals Begins Operations at Greenfield API Facility
Senores Pharmaceuticals Limited (‘Senores’ or ‘SPL’) has today inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (API) plant located at Survey No. 1503, Rajpur, Kadi, Mehsana - 382 715, Gujarat. Spread across approximately

Senores Pharmaceuticals Limited (‘Senores’ or ‘SPL’) has today inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (API) plant located at Survey No. 1503, Rajpur, Kadi, Mehsana – 382 715, Gujarat.
Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores’ second API manufacturing facility, adding significantly to the existing API manufacturing capabilities.
Commenting on the inauguration, Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said:
“We are delighted to commence operations at our greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the Regulated Markets, especially in the CDMO/CMO business.”
About Senores Pharmaceuticals Company Limited:
Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The companies’ current portfolio includes 24 ANDA and 21 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 260 product registrations and 530 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).
Senores has 2 manufacturing facilities for formulations– one in Atlanta, US which is USFDA approved and DEA/BAA compliant & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India)